BenevolentAI SA
AEX:BAI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BenevolentAI SA
Other Operating Expenses
BenevolentAI SA
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BenevolentAI SA
AEX:BAI
|
Other Operating Expenses
£423k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Other Operating Expenses
£1.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
28%
|
CAGR 10-Years
14%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Other Operating Expenses
$252m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-17%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Other Operating Expenses
$2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Other Operating Expenses
£5.6m
|
CAGR 3-Years
93%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Other Operating Expenses
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BenevolentAI SA
Glance View
BenevolentAI SA is a holding company that engages in the research and development and sale of AI-enabled drugs. The firm through the combined capabilities of its AI platform, scientific ability and wet-lab facilities deliver new drug candidates with a higher probability of clinical success than those developed using traditional methods. The company has an array of scientifically validated discoveries. The Company, through its BenevolentAI Platform, offers in-house pipeline of over 20 disease programs, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies, such as AstraZeneca, as well as other research and charitable institutions.
See Also
What is BenevolentAI SA's Other Operating Expenses?
Other Operating Expenses
423k
GBP
Based on the financial report for Dec 31, 2023, BenevolentAI SA's Other Operating Expenses amounts to 423k GBP.
What is BenevolentAI SA's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 1Y
155%
Over the last year, the Other Operating Expenses growth was 155%.
